International braz j urol · 2019 · 28 citations · 16 references
MedicineOncologyUrologyGenitourinary OncologyTumor ProgressionUrologic OncologyBiomarkers In Genitourinary CancerBiomarkers In Urologic OncologyBladder CancerBladder SurgeryTherapy Response AssessmentBladder Tumor SurgeryMuscle-invasive Bladder Cancer TherapyNeutrophil-to-lymphocyte RatioNon-muscle-invasive Bladder Cancer ImmunotherapyNon-muscle-invasive Bladder Cancer TherapyPrognostic BiomarkersPrognostic Classification
OBJECTIVES: To evaluate the neutrophil-to-lymphocyte ratio (NLR) as a prognostic factor for response of high risk non muscle invasive bladder cancer (HRNMIBC) treated with BCG therapy. MATERIALS AND METHODS: Between March 2010 and February 2014 in a tertiary center 100 consecutive patients with newly diagnosed HRNMIBC were retrospectively analyzed. Patients were divided according to NLR value: 46 patients with NLR value less than 3 (NLR < 3 group), and 54 patients with NLR value more than 3 (NLR ≥ 3 group). At the end of follow-up 52 patients were high grade disease free (BCG-responder group) and 48 patients underwent radical cystectomy for high grade recurrence or progression to muscle invasive disease (BCG non-responder group). The average follow-up was 60 months. INTERVENTION: analysis and correlation of preoperative NLR value with response to BCG in terms of recurrence and progression. RESULTS: The optimal cut-off for NLR was ≥ 3 according to the receiver operating characteristics analysis (AUC 0.760, 95% CI, 0.669-0.850). Mean NLR value was 3.65 ± 1.16 in BCG non-responder group and 2.61 ± 0.77 in BCG responder group (p = 0.01). NLR correlated with recurrence (r = 0.55, p = 0.01) and progression risk scores (r = 0.49, p = 0.01). In multivariate analysis, NLR (p = 0.02) and EORTC recurrence risk groups (p = 0.01) were associated to the primary endpoint. The log-rank test showed statistically significant difference between NLR < 3 and NLR ≥ 3 curves (p < 0.05). CONCLUSIONS: NLR value preoperatively evaluated could be a useful tool to predict BCG response of HRNMIBC. These results could lead to the development of prospective studies to assess the real prognostic value of NLR in HRNMIBC.
16
Christina Fitzmaurice, Christine A. Allen, Ryan M Barber et al. · JAMA Oncology · 2016 · 6.3K citations · Full text
Richard Sylvester, Adrian P.M. van der Meijden, Willem Oosterlinck et al. · European Urology · 2006 · 3K citations
EAU Guidelines on Non–Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016
Marko Babjuk, Andreas Böhle, Maximilian Burger et al. · European Urology · 2016 · 2.3K citations
Morgan Rouprêt, Marko Babjuk, Éva Compérat et al. · European Urology · 2015 · 1.3K citations